Brokerages Set Generate Biomedicines Inc (NASDAQ:GENB) Target Price at $23.20

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $23.20.

A number of analysts have recently issued reports on the company. Zacks Research raised Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Guggenheim assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective for the company. Piper Sandler assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective for the company. Morgan Stanley assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating for the company.

Generate Biomedicines Stock Down 2.7%

GENB opened at $12.12 on Friday. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.